Crystal Polymorph Screening for Pharmaceuticals 'SingleCrystal'
Dynamically generate diffraction patterns of crystal polymorphs in collaboration with CrystalMaker.
In the pharmaceutical industry, the polymorphism of drugs is a crucial factor that significantly affects efficacy and stability. Polymorphs with different crystal structures have varying solubility and bioavailability, directly impacting the quality and effectiveness of the product. SingleCrystal supports the identification and characterization of crystal structures through diffraction pattern simulations. In collaboration with CrystalMaker, it visualizes crystal structures while dynamically generating diffraction patterns, streamlining the analysis of polymorphs. This deepens the understanding of crystal polymorphism in drug development and contributes to the development of higher-quality pharmaceuticals. [Use Cases] - Screening of crystal polymorphs for drug candidate compounds - Identification and characterization of crystal structures - Simulation of diffraction patterns and comparison with experimental data [Benefits of Implementation] - Rapid identification and characterization of crystal polymorphs - Increased efficiency in the drug development process - Improvement in product quality and assurance of stability
- Company：ヒューリンクス
- Price：Other
